{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T14:36:30Z","timestamp":1776954990378,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-89977-z","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T14:56:23Z","timestamp":1739372183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic inflammation index is a predictive and prognostic factor in patients with liposarcoma or leiomyosarcoma treated with trabectedin"],"prefix":"10.1038","volume":"15","author":[{"given":"Pawel","family":"Sobczuk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina","family":"Filipowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukasz","family":"Lamparski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Kosela-Paterczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawel","family":"Teterycz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Kozak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Rogala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"\u015awitaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u0142awomir","family":"Falkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"89977_CR1","unstructured":"Gronchi, A. et al. Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: results of the expanded cohort of a Randomized Trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish sarcoma groups (PSG). J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol. JCO2300908. (2024)."},{"issue":"8","key":"89977_CR2","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon, A. et al. Efficacy of Larotrectinib in TRK Fusion-positive cancers in adults and children. N Engl. J. Med. 378 (8), 731\u2013739 (2018).","journal-title":"N Engl. J. Med."},{"issue":"23","key":"89977_CR3","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9, T. et al. Pembrolizumab in microsatellite-instability\u2013high Advanced Colorectal Cancer. N Engl. J. Med. 383 (23), 2207\u20132218 (2020).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"89977_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Efficacy of Pembrolizumab in patients with Noncolorectal high microsatellite Instability\/Mismatch repair-deficient Cancer: results from the phase II KEYNOTE-158 study. J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol. 38 (1), 1\u201310 (2020).","journal-title":"J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol."},{"issue":"5","key":"89977_CR5","first-page":"793","volume":"10","author":"Y Guan","year":"1993","unstructured":"Guan, Y., Sakai, R., Rinehart, K. L. & Wang, A. H. Molecular and crystal structures of ecteinascidins: potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata. J. Biomol. Struct. Dyn. 10 (5), 793\u2013818 (1993).","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"8","key":"89977_CR6","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","volume":"34","author":"GD Demetri","year":"2016","unstructured":"Demetri, G. D. et al. Efficacy and safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized Multicenter Clinical Trial. J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol. 34 (8), 786\u2013793 (2016).","journal-title":"J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol."},{"issue":"8","key":"89977_CR7","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.annonc.2021.04.014","volume":"32","author":"AL Cesne","year":"2021","unstructured":"Cesne, A. L. et al. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. Ann. Oncol. 32 (8), 1034\u20131044 (2021).","journal-title":"Ann. Oncol."},{"issue":"25","key":"89977_CR8","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1200\/JCO.2008.21.0088","volume":"27","author":"GD Demetri","year":"2009","unstructured":"Demetri, G. D. et al. Efficacy and safety of Trabectedin in patients with Advanced or Metastatic Liposarcoma or Leiomyosarcoma after failure of prior anthracyclines and Ifosfamide: results of a Randomized Phase II study of two different schedules. J. Clin. Oncol. 27 (25), 4188\u20134196 (2009).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"89977_CR9","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1200\/JCO.2005.01.180","volume":"23","author":"A Le Cesne","year":"2005","unstructured":"Le Cesne, A. et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol. 23 (3), 576\u2013584 (2005).","journal-title":"J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol."},{"issue":"24","key":"89977_CR10","doi-asserted-by":"publisher","first-page":"5484","DOI":"10.1200\/JCO.2005.05.028","volume":"23","author":"R Garcia-Carbonero","year":"2005","unstructured":"Garcia-Carbonero, R. et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol. 23 (24), 5484\u20135492 (2005).","journal-title":"J. Clin. Oncol. Off J. Am. Soc. Clin. Oncol."},{"issue":"6","key":"89977_CR11","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/cncr.32661","volume":"126","author":"H Kobayashi","year":"2020","unstructured":"Kobayashi, H. et al. Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: a Japanese Musculoskeletal Oncology Group study. Cancer 126 (6), 1253\u20131263 (2020).","journal-title":"Cancer"},{"issue":"5","key":"89977_CR12","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3390\/cancers13051053","volume":"13","author":"E Palmerini","year":"2021","unstructured":"Palmerini, E. et al. Trabectedin for patients with Advanced Soft tissue sarcoma: a non-interventional, retrospective, Multicenter Study of the Italian Sarcoma Group. Cancers 13 (5), 1053 (2021).","journal-title":"Cancers"},{"issue":"4","key":"89977_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/ijc.34309","volume":"152","author":"B Vincenzi","year":"2023","unstructured":"Vincenzi, B. et al. Trabectedin use in soft-tissue sarcoma patients in a real-world setting: data from an Italian national drug-access registry. Int. J. Cancer. 152 (4), 761\u2013768 (2023).","journal-title":"Int. J. Cancer"},{"issue":"21","key":"89977_CR14","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.3390\/cancers14215234","volume":"14","author":"V Gr\u00fcnwald","year":"2022","unstructured":"Gr\u00fcnwald, V. et al. Trabectedin for patients with Advanced Soft tissue sarcoma: a non-interventional, prospective, Multicenter, Phase IV Trial. Cancers 14 (21), 5234 (2022).","journal-title":"Cancers"},{"issue":"4","key":"89977_CR15","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/cancers13040792","volume":"13","author":"J Mart\u00ednez-Trufero","year":"2021","unstructured":"Mart\u00ednez-Trufero, J. et al. A growth Modulation Index-based GEISTRA score as a New Prognostic Tool for Trabectedin Efficacy in patients with Advanced Soft tissue sarcomas: a Spanish Group for Sarcoma Research (GEIS) Retrospective Study. Cancers 13 (4), 792 (2021).","journal-title":"Cancers"},{"issue":"6","key":"89977_CR16","first-page":"742","volume":"51","author":"A Le Cesne","year":"2015","unstructured":"Le Cesne, A. et al. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. Eur. J. Cancer Oxf. Engl. 1990. 51 (6), 742\u2013750 (2015).","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"issue":"3","key":"89977_CR17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.suronc.2018.07.012","volume":"27","author":"DY Garc\u00eda-Ortega","year":"2018","unstructured":"Garc\u00eda-Ortega, D. Y. et al. Neutrophil\/lymphocyte ratio is associated with survival in synovial sarcoma. Surg. Oncol. 27 (3), 551\u2013555 (2018).","journal-title":"Surg. Oncol."},{"issue":"2","key":"89977_CR18","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/ijc.28677","volume":"135","author":"J Szkandera","year":"2014","unstructured":"Szkandera, J. et al. The lymphocyte\/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int. J. Cancer 135 (2), 362\u2013370 (2014).","journal-title":"Int. J. Cancer"},{"issue":"3","key":"89977_CR19","first-page":"3373","volume":"18","author":"P Sobczuk","year":"2019","unstructured":"Sobczuk, P. et al. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in patients with advanced gastrointestinal stromal tumors treated with sunitinib after imatinib failure. Oncol. Lett. 18 (3), 3373\u20133380 (2019).","journal-title":"Oncol. Lett."},{"issue":"10","key":"89977_CR20","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s12094-020-02324-8","volume":"22","author":"D Vi\u00f1al","year":"2020","unstructured":"Vi\u00f1al, D. et al. Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas. Clin. Transl Oncol. 22 (10), 1849\u20131856 (2020).","journal-title":"Clin. Transl Oncol."},{"issue":"13","key":"89977_CR21","doi-asserted-by":"publisher","first-page":"5383","DOI":"10.1158\/0008-5472.CAN-08-3845","volume":"69","author":"I Ray-Coquard","year":"2009","unstructured":"Ray-Coquard, I. et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 69 (13), 5383\u20135391 (2009).","journal-title":"Cancer Res."},{"issue":"4","key":"89977_CR22","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.3390\/cancers15041080","volume":"15","author":"V Fausti","year":"2023","unstructured":"Fausti, V. et al. Systemic inflammatory indices in second-line soft tissue sarcoma patients: focus on Lymphocyte\/Monocyte ratio and Trabectedin. Cancers 15 (4), 1080 (2023).","journal-title":"Cancers"},{"issue":"4","key":"89977_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.21873\/cdp.10040","volume":"1","author":"Y Sato","year":"2021","unstructured":"Sato, Y. et al. Changes in neutrophil-to-lymphocyte ratio Predict Efficacy of Trabectedin for Soft-tissue sarcoma. Cancer Diagn. Progn. 1 (4), 303\u2013308 (2021).","journal-title":"Cancer Diagn. Progn."},{"issue":"9829","key":"89977_CR24","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WT van der Graaf","year":"2012","unstructured":"van der Graaf, W. T. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379 (9829), 1879\u20131886 (2012).","journal-title":"Lancet"},{"issue":"3","key":"89977_CR25","doi-asserted-by":"publisher","first-page":"e0280508","DOI":"10.1371\/journal.pone.0280508","volume":"18","author":"A Ohmoto","year":"2023","unstructured":"Ohmoto, A. et al. Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: a retrospective study. PloS One 18 (3), e0280508 (2023).","journal-title":"PloS One"},{"issue":"8","key":"89977_CR26","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.3390\/cancers14081879","volume":"14","author":"S Kokkali","year":"2022","unstructured":"Kokkali, S. et al. A Multicenter, prospective, observational study to assess the clinical activity and impact on Symptom Burden and patients\u2019 quality of life in patients with Advanced Soft Tissue Sarcomas Treated with trabectedin in a Real-World setting in Greece. Cancers 14 (8), 1879 (2022).","journal-title":"Cancers"},{"issue":"2","key":"89977_CR27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/annonc\/mds470","volume":"24","author":"N Penel","year":"2013","unstructured":"Penel, N. et al. Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. Ann. Oncol. 24 (2), 537\u2013542 (2013).","journal-title":"Ann. Oncol."},{"key":"89977_CR28","doi-asserted-by":"publisher","unstructured":"Differential response of primary. and metastatic melanomas to neutrophils attracted by IL-8 - Schaider \u2013\u20092003 - International Journal of Cancer - Wiley Online Library [Internet]. [cited 2024 Dec 16].  https:\/\/doi.org\/10.1002\/ijc.10775.","DOI":"10.1002\/ijc.10775"},{"issue":"7","key":"89977_CR29","first-page":"2406","volume":"139","author":"A el-Hag","year":"1987","unstructured":"el-Hag, A. & Clark, R. A. Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J. Immunol. Baltim. Md. 1950 139 (7), 2406\u20132413 (1987).","journal-title":"J. Immunol. Baltim. Md. 1950"},{"issue":"12","key":"89977_CR30","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1161\/ATVBAHA.110.207514","volume":"30","author":"S Jain","year":"2010","unstructured":"Jain, S., Harris, J., Ware, J.  Platelets. Arterioscler. Thromb. Vasc Biol. 30(12):2362\u20132367. (2010).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"issue":"6","key":"89977_CR31","first-page":"1295","volume":"59","author":"B Nieswandt","year":"1999","unstructured":"Nieswandt, B., Hafner, M., Echtenacher, B. & M\u00e4nnel, D. N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 59 (6), 1295\u20131300 (1999).","journal-title":"Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89977-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89977-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89977-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T14:56:28Z","timestamp":1739372188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89977-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["89977"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-89977-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"29 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PS reports personal payment or honoraria for participation in lectures, presentations, speakers bureaus, manuscript writing, or educational events from Bristol-Myers Squibb, Gilead, and Sandoz; and personal support for attending meetings from Bristol-Myers Squibb, Novartis, and Pierre-Fabre; PS also serves as a board or committee member of Sandoz, the Polish Society of Clinical Oncology (unpaid), the European Society of Medical Oncology (unpaid), and the Connective Tissue Oncology Society (unpaid); PS also holds personal stocks at Celon Pharma.PR reports personal consulting fees from Bristol-Myers Squibb, MSD, Novartis, Pierre Fabre, Philogen, Pfizer, Genesis, and Madison Pharma; payment or honoraria for participating in lectures, presentations, speakers bureaus, manuscript writing, or educational events from Bristol-Myers Squibb, MSD, Novartis, Pfizer, Pierre Fabre, Sanofi, Merck, and AstraZeneca; personal support for attending meetings from Orphan Europe and Pierre Fabre. Other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent for treatment in routine clinical practice was obtained from all patients. Additional consent for the retrospective analyses was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"5247"}}